Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma

NCT03207867 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT03207867
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03207867 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
August 28, 2017
Completion date
February 14, 2023
Enrollment
315 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

dlbcl, diffused large b cell lymphoma, head and neck cancer, mcrpc, metastatic castration resistant prostate cancer, melanoma, mss, microsatellite stable colon cancer, nsclc, non small cell lung cancer, pancreatic cancer, rcc, renal cell cancer, tnbc, triple negative breast cancer, urothelial cancer